These recent findings justify our explorative work looking at RIOK1 inhibition in the context of MSI-High CRC population to determine if RIOK1 could create an SL phenotype in CRC MSI-High p53 cancers by targeting pathways downstream of the p53 cascade that is unique from the ones currently under clinical evaluation. This evidence concerns the gene RIOK1 and colorectal carcinoma.